Aridis Pharmaceuticals 2024 Investor Presentation Respiratory Therapeutics

Aridis Pharmaceuticals is a late-stage clinical biotech company developing innovative therapeutics for respiratory and infectious diseases. The company's lead asset AR-301 is in Phase 3 development for acute pneumonia treatment, with a ~$1 billion market opportunity, while AR-501 in cystic fibrosis has met Phase 2 endpoints.